

Volume 28 (2012) Index

- Abrishami, Payam. *See* Hulstaert
Acción, Beatriz Casal. *See* Varela-Lema
Akehurst, Ron. *See* Cooper
Asseburg, Christian, Piia Peura, Tuija Oksanen, Juha Turunen, Timo Purmonen, and Janne Martikainen. Cost-effectiveness of oral triptans for acute migraine: Mixed treatment comparison, 382
Atallah, Álvaro Nagib. *See* Silva
Attieh, Randa. *See* Gagnon
Augustovski, Federico. *See* Pichon-Riviere
Augustovsky, Federico. *See* Poggio
Autti-Rämö, Ilona. *See* Mäklin
- Barnes, Steven. *See* Lyratzopoulos
Barnett-Page, Elaine. *See* Cooper
Bastani, Peivand, and Aliasghar Ahmad Kiadaliri. Cost-utility analysis of adjuvant therapies for breast cancer in Iran, 110
Baxter, Louise. *See* Hartwell
Bech, Mickael. *See* Kidholm
Belotti, Laura Maria Beatrice. *See* Berti
Bending, Matthew, John Hutton, and Clare McGrath. A comparison of pharmaceutical reimbursement agencies' processes and methods in France and Scotland, 187
Benedict, Ágnes. *See* Sorensen
Benguria-Arrate, Gaizka. *See* Gutierrez-Ibarluzea
Berti, Elena, Laura Maria Beatrice Belotti, Filippo Cademartiri, Tiziana Giovannini, Rossana De Palma, and Roberto Grilli. Impact of computed tomography coronary angiography on other diagnostic tests, 424
Bittner, Uta. *See* Dengler
Blasco-Amaro, Juan Antonio. *See* Varela-Lema
Blauvelt, Barri M. *See* Gallego
Boulé, Normand G. *See* Coyle
Bouwmans, Clazien A. M. *See* Tan
Bowen, James M. *See* Lim
Bowes, Alison. *See* Kidholm
Braunack-Mayer, Annette. *See* Hofmann
Bridges, John F. P. *See* Gallego
Bronstein, Alvin C. *See* Galvao
Buxton, Martin. *See* Youn
- Cademartiri, Filippo. *See* Berti
Cafazzo, Joseph A. *See* Chan
Campbell, Bruce. *See* Lyratzopoulos
Caporale, Joaquín. *See* Poggio
Cerbo, Marina. *See* Migliore
Chan, Alvita J., Julie Chan, Joseph A. Cafazzo, Peter G. Rossos, Tim Tripp, Kaveh Shojania, Tanya Khan, and Anthony C. Easty. Order sets in health care: A systematic review of their effects, 235
Chan, Julie. *See* Chan
Chen, Connie. *See* Sorensen
Chuck, Andy. *See* Thanh
Cicchetti, Americo. *See* Ruggeri
Clark, Michelle. *See* Morrison
Cleemput, Irina. *See* Franken
Cleemput, Irina. European drug reimbursement systems' legitimacy: Five-country comparison and policy tool, 358
Clegg, Andy. *See* Cooper
Clement, Fiona M. *See* Leggett
Clement, Fiona. *See* Noseworthy
Clifford, Tammy. *See* Morrison
Cooper, Katy L., Patrick Fitzgerald, Kerry Dillingham, Kawitha Vardeva, and Ron Akehurst. Romiplostim and eltrombopag for immune thrombocytopenia: Methods for indirect comparison, 249
Cooper, Keith, Jo Picot, Jeremy Jones, Josephine Kavanagh, Angela Harden, Elaine Barnett-Page, Andy Clegg, Debbie Hartwell, Geoff Frampton, and Alison Price. An economic model of school-based behavioral interventions to prevent sexually transmitted infections, 407
Coyle, Doug, Kathryn Coyle, Glen P. Kenny, Normand G. Boulé, George A. Wells, Michelle Fortier, Robert D. Reid, Penny Phillips, and Ronald J. Sigal. Cost-effectiveness of exercise programs in type 2 diabetes, 228
Coyle, Kathryn. *See* Coyle
- d'Oliveira, Alexandre Lemgruber Portugal. *See* Silva
da Silva, Edina Mariko Koga. *See* Silva
de Almeida, Rosimary Terezinha. *See* Silva
de Mesquita, Aline Monte. *See* Silva
De Palma, Rossana. *See* Berti
Dengler, Kathrin, and Uta Bittner. What do we mean by talking about "value(s)"? A Reply to Saarni et al., 195
Dibidino, Rossella. *See* Ruggeri
Dillingham, Kerry. *See* Cooper
Drummond, Michael. *See* Pichon-Riviere
Drummond, Michael, Peter Neumann, Bengt Jönsson, Bryan Luce, J. Sanford Schwartz, Uwe Siebert, and Sean D. Sullivan, for the International Group for HTA Advancement. Can we reliably benchmark health technology assessment organizations?, 159
Dyer, Suzanne. *See* Staub
- Eandi, Mario. *See* Pradelli
Easty, Anthony C. *See* Chan
Ehlers, Lars, and Morten Berg Jensen. Attitudes and barriers toward mini-HTA in the Danish municipalities, 271
Ekeland, Anne Granström. *See* Kidholm
Elias, Flávia Tavares Silva. *See* Pichon-Riviere
Elias, Flávia Tavares Silva. *See* Silva
Elshaug, Adam G. *See* Watt
- Fenlon, Helen. *See* Hanly
Fiander, Michelle. *See* Morrison
Fitzgerald, Patrick. *See* Cooper
Flamion, Bruno. *See* Hulstaert
Flottorp, Signe Agnes. *See* Kidholm
Flynn, Terry. *See* Gallego
Forsetlund, Louise, Ingvild Kirkehei, Ingrid Harboe, and Jan Odgaard-Jensen. A comparison of two search methods for determining the scope of systematic reviews and health technology assessments, 59
Fortier, Michelle. *See* Coyle
Frampton, Geoff. *See* Cooper
Franken, Margreet, Maité le Polain, Irina Cleemput, and Marc Koopmanschap. Comparison of European drug reimbursement systems, 349
Frønsdal, Katrine, Franz Pichler, Logan Mardhani-Bayne, Chris Henshall, John-Arne Røttingen, Berit Mørland, and Marianne Klemp. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry, 374
Fung, Matthew. *See* Packer
- Gagnon, Marie-Pierre, and Randa Attieh. Implementation of local/hospital-based health technology assessment initiatives in low- and middle-income countries, 445
Gallego, Gisselle, John F. P. Bridges, Terry Flynn, Barri M. Blauvelt, and Louis W. Niessen. Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies, 339
Gallo, Pedro. *See* Sampietro-Colom
Galvão, Tais Freire. *See* Silva
Galvao, Tais F., Everton N. Silva, Marcus T. Silva, Alvin C. Bronstein, and Mauricio G. Pereira. Economic evaluation of poison centers: A systematic review, 86
Gao, Lan, Fei-Li Zhao, and Shu-Chuen Li. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China, 436
Garattini, Silvio. *See* Hulstaert
García, Marisa López. *See* Varela-Lema

- Gartlehner, Gerald, Suzanne L. West, Alyssa J. Mansfield, Charles Poole, Elizabeth Tant, Linda J. Lux, and Kathleen N. Lohr. Clinical heterogeneity in systematic reviews and health technology assessments: Synthesis of guidance documents and the literature, 36
- Gava, Cintia Maria. *See* Silva
- Geiger-Gritsch, Sabine. *See* Mad
- Gillespie, Paddy, Eamon O'Shea, Gillian Paul, Tom O'Dowd, and Susan M. Smith. Cost effectiveness of peer support for type 2 diabetes, 3
- Giorgetti, Carla. *See* Sorensen
- Giovannini, Tiziana. *See* Berti
- Girling, Alan. *See* Youn
- Goeree, Ron. *See* Lim
- Goh, Jo Wern. *See* Sorensen
- Golder, Su, and Yoon K. Loke. The contribution of different information sources for adverse effects data, 133
- Goodman, Clifford. Toward international good practices in health technology assessment, 169
- Grilli, Roberto. *See* Berti
- Gross, Dominik. *See* Laryionava
- Gutierrez-Ibarluzea, Iñaki, and Sue Simpson, Gaizka Benguria-Arrate and the Members of EuroScan International Network. Early awareness and alert systems: An overview of EuroScan methods, 301
- Gutierrez-Ibarluzea, Iñaki. *See* Packer
- Gutierrez-Moreno, Santiago. *See* Sampietro-Colom
- Gutiérrez-Ibarluzea, Inaki. *See* Varela-Lema
- Hakak, Nina. *See* Tal
- Hanly, Paul, Mairead Skally, Helen Fenlon, and Linda Sharp. Cost-effectiveness of computed tomography colonography in colorectal cancer screening: A systematic review, 415
- Harboe, Ingrid. *See* Forsetlund
- Harden, Angela. *See* Cooper
- Hartwell, Debbie. *See* Cooper
- Hartwell, Debbie, Jeremy Jones, Louise Baxter, and Jonathan Shepherd. Shortened peginterferon and ribavirin treatment for chronic hepatitis C, 398
- Hemming, Karla. *See* Youn
- Henshall, Chris. *See* Frønsdal
- Henshall, Chris, Tara Schuller, and Logan Mardhani-Bayne, on behalf of the HTAI Policy Forum. Using health technology assessment to support optimal use of technologies in current practice: The challenge of "disinvestment", 203
- Henshall, Chris. Describe decision-making systems, assess health technology assessment reports, 168
- Hiller, Janet E. *See* Watt
- Hinterreiter, Gerda. *See* Mad
- Hodgetts, Katherine. *See* Watt
- Hofmann, Bjørn, Samuli I. Saarni, Annette Braunack-Mayer, and Gert Jan van der Wilt. To evaluate versus to know the value of everything, 196
- Huić, Mirjana. *See* Hulstaert
- Hulstaert, Frank, Mattias Neyt, Imgard Vinck, Sabine Stordeer, Mirjana Huić, Stefan Sauerland, Marja R. Kuijpers, Payam Abrishami, Hindrik Vondeling, Bruno Flamion, Silvio Garattini, Mira Pavlovic, and Hans van Brabant. Pre-market clinical evaluations of innovative high-risk medical devices in Europe, 278
- Hurley, Jerry. *See* Lim
- Husereau, Don. *See* Morrison
- Hutton, Brian. *See* Morrison
- Hutton, John. *See* Bending
- Iannazzo, Sergio. *See* Pradelli
- Ibargoyen-Roteta, Nora. *See* Varela-Lema
- Ilonen, Terhi. *See* Mäkelä
- Imaz, Inaki. *See* Varela-Lema
- Irazola, Vilma. *See* Poggio
- Iyer, Shrividya. *See* Sorensen
- Jacobs, Philip. *See* Thanh
- Jefferson, Tom. *See* Migliore
- Jensen, Lise Kvistgaard. *See* Kidholm
- Jensen, Morten Berg. *See* Ehlers
- Johri, Mira, and Ole Frithjof Norheim. Can cost-effectiveness analysis integrate concerns for equity? Systematic review, 125
- Jones, Jeremy. *See* Cooper
- Jones, Jeremy. *See* Hartwell
- Jönsson, Bengt. *See* Drummond
- Kasonde, Joseph. *See* Mwape
- Kavanagh, Josephine. *See* Cooper
- Kenny, Glen P. *See* Coyle
- Khan, Tanya. *See* Chan
- Kiadaliri, Aliasghar Ahmad. *See* Bastani
- Kidholm, Kristian, Anne Granstrom Ekeland, Lise Kvistgaard Jensen, Janne Rasmussen, Claus Duedal Pedersen, Alison Bowes, Signe Agnes Flottorp, and Mickael Bech. A model for assessment of telemedicine applications: MAST, 44
- Kirkehei, Ingvild. *See* Forsetlund
- Klemp, Marianne. *See* Frønsdal
- Knopf, Kevin. *See* Sorensen
- Kolasa, Katarzyna, and Radek Wasiak. Health technology assessment in Poland and Scotland: Comparison of process and decisions, 70
- Koopmanschap, Marc. *See* Franken
- Kovanen, Niina. *See* Mäklin
- Kuijpers, Marja R. *See* Hulstaert
- Laitinen, Riikka. *See* Mäklin
- Laryionava, Katsiaryna, and Dominik Gross. Deus Ex Machina or E-slave? Public perception of healthcare robotics in the German print media, 265
- le Polain, Maïté. *See* Franken
- Leggett, Laura, Tom W. Noseworthy, Mahmood Zarrabi, Diane Lorenzetti, Lloyd R. Sutherland, and Fiona M. Clement. Health technology reassessment of non-drug technologies: Current practices, 220
- Li, Shu-Chuen. *See* Gao
- Lim, Morgan E., Tim Nye, James M. Bowen, Jerry Hurley, Ron Goeree, and Jean-Eric Tarride. Mathematical modeling: The case of emergency department waiting times, 93
- Lohr, Kathleen N. *See* Gartlehner
- Loke, Yoon K. *See* Golder
- Lombardi, Celestino Pio. *See* Ruggeri
- Lord, Joanne. *See* Youn
- Lord, Sarah J. *See* Staub
- Lorenzetti, Diane. *See* Leggett
- Lu, Lanting, Jaime L. Peters, Chris Roome, and Ken Stein. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia, 241
- Luce, Bryan. *See* Drummond
- Lux, Linda J. *See* Gartlehner
- Lyratzopoulos, Georgios, Steven Barnes, Heather Stegenga, Suzi Peden, and Bruce Campbell. Updating clinical practice recommendations: Is it worthwhile and when?, 29
- Mad, Philipp, Sabine Geiger-Gritsch, Gerda Hinterreiter, Stefan Mathis-Edenhofer, and Claudia Wild. Pre-coverage assessments of new hospital interventions on Austria: Methodology and 3 years of experience, 171
- Mäkelä, Marjukka and Terhi Ilonen. Statistics and thanks, 1
- Mäkelä, Marjukka. Exchanging views on HTA, 85
- Mäklin, Suvii, Pirjo Räsänen, Riikka Laitinen, Niina Kovanen, Ilona Autti-Rämö, Harri Sintonen, and Risto P. Roine. Quality-adjusted life-years for the estimation of effectiveness of screening programs: A systematic literature review, 145
- Mansfield, Alyssa J. *See* Gartlehner
- Marchetti, Marco. *See* Ruggeri
- Mardhani-Bayne, Logan. *See* Frønsdal
- Mardhani-Bayne, Logan. *See* Henshall
- Martikainen, J. Should the decision-making process of reimbursing medicines be improved?, 347
- Martikainen, Janne. *See* Asseburg
- Martí, Sebastián García. *See* Pichon-Riviere
- Martín, Miguel. *See* Sorensen
- Mathis-Edenhofer, Stefan. *See* Mad
- McGrath, Clare. *See* Bending
- Mierzwinski-Urban, Monika. *See* Morrison
- Migliore, Antonio, Maria Rosaria Perrini, Tom Jefferson, and Marina Cerbo. Implementing a national early awareness and alert system for new and emerging health technologies in Italy: The COTE project, 321
- Miriuka, Santiago. *See* Poggio
- Morilla-Bachs, Irene. *See* Sampietro-Colom
- Mørland, Berit. *See* Frønsdal
- Morrison, Andra, Julie Polisena, Don Husereau, Kristen Moulton, Michelle Clark, Michelle Fiander, Monika Mierzwinski-Urban, Tammy Clifford, Brian Hutton, and Danielle Rabb. The effect of English-language restriction on systematic review-based meta-analyses: A systematic review of empirical studies, 138
- Morrison, Andra. Scanning the Horizon in a decentralized healthcare system: The Canadian experience, 327
- Mota, Teresa Cerdá. *See* Varela-Lema
- Moulton, Kristen. *See* Morrison
- Muscaritoli, Maurizio. *See* Pradelli

- Mwape, Lonia, Prudencia Mweemba, and Joseph Kasonde. Strengthening the health system to enhance mental health in Zambia: A policy brief, 294
Mweemba, Prudencia. *See* Mwape
- Neumann, Peter. *See* Drummond
Neyt, Mattias. *See* Hulstaert
Niessen, Louis W. *See* Gallego
Norheim, Ole Frithjof. *See* Johri
Norris, Pauline. *See* Ragupathy
Noseworthy, Tom, and Fiona Clement. Health technology reassessment: Scope, methodology, & language, 201
Noseworthy, Tom W. *See* Leggett
Nye, Tim. *See* Lim
- O'Dowd, Tom. *See* Gillespie
O'Shea, Eamon. *See* Gillespie
Odgaard-Jensen, Jan. *See* Forsetlund
Ohinmaa, Arto. *See* Thanh
Oksanen, Tuija. *See* Asseburg
- Packer, Claire, Iñaki Gutierrez-Ibarluzea, and Sue Simpson. The evolution of early awareness and alert methods and systems, 199
Packer, Claire, Matthew Fung, and Andrew Stevens. Analyzing 10 years of early awareness and alert activity in the United Kingdom, 308
Pan, Feng. *See* Sorensen
Paul, Gillian. *See* Gillespie
Pavlovic, Mira. *See* Hulstaert
Peden, Suzi. *See* Lyratzopoulos
Pedersen, Claus Duedal. *See* Kidholm
Pereira, Mauricio G. *See* Galvao
Perrini, Maria Rosaria. *See* Migliore
Peters, Jaime L. *See* Lu
Peura, Piia. *See* Asseburg
Phillips, Penny. *See* Coyle
Pichler, Franz. *See* Frønsdal
Pichon-Riviere, Andres, Federico Augustovski, Sebastián García Martí, Sean D. Sullivan, and Michael Drummond. Transferability of health technology assessment reports in Latin America: An exploratory survey of researchers and decision makers, 180
Pichon-Riviere, Andres, Flávia Tavares Silva Elias, Verónica Gallegos Rivero, and Claudia P. Vaca. Early awareness and alert activities in Latin America: Current situation in four countries, 315
Picot, Jo. *See* Cooper
Poggio, Rosana, Federico Augustovsky, Joaquín Caporale, Vilma Irazola, and Santiago Miriuka. Cost-effectiveness of cardiac resynchronization therapy: Perspective from Argentina, 429
Polisena, Julie. *See* Morrison
Poole, Charles. *See* Gartlehner
Pradelli, Lorenzo, Sergio Iannazzo, Orietta Zaniolo, Maurizio Muscaritoli, and Mario Eandi. Effectiveness and cost-effectiveness of supplemental glutamine dipeptide in total parenteral nutrition therapy for critically ill patients: A discrete event simulation model based on Italian data, 22
Price, Alison. *See* Cooper
Punal-Riobóo, Jeanette. *See* Varela-Lema
Purmonen, Timo. *See* Asseburg
- Rabb, Danielle. *See* Morrison
Raffaelli, Marco. *See* Ruggeri
Ragupathy, Rajan, June Tordoff, Pauline Norris, and David Reith. Key informants' perceptions of how PHARMAC operates in New Zealand, 367
Räsänen, Pirjo. *See* Mäklin
Rasmussen, Janne. *See* Kidholm
Reid, Robert D. *See* Coyle
Reith, David. *See* Ragupathy
Rivero, Verónica Gallegos. *See* Pichon-Riviere
Roijen, Leona Hakkaart-van. *See* Tan
Roine, Risto P. *See* Mäklin
Ronchini, Misani Akiko Kanamota. *See* Silva
Roome, Chris. *See* Lu
Rossos, Peter G. *See* Chan
Röttingen, John-Arne. *See* Frønsdal
Ruano-Ravina, Alberto. *See* Varela-Lema
Ruano-Ravina, Alberto. *See* Varela-Lema
Ruggeri, Matteo, Rossella Dibidino, Marco Marchetti, Celestino Pio Lombardi, Marco Raffaelli, and Americo Cicchetti. The harmonic study: Cost-effectiveness evaluation of the use of the ultrasonic scalpel in total thyroidectomy, 259
Rutten, Frans F. H. *See* Tan
- Saarni, Samuli I. *See* Hofmann
Sampietro-Colom, Laura. *See* Varela-Lema
Sampietro-Colom, Laura, Irene Morilla-Bachs, Santiago Gutierrez-Moreno, and Pedro Gallo. Development and test of a decision support tool for hospital health technology assessment, 460
Sampietro-Colom, Laura. Consider context and stakeholders, 166
Santos, Vania Cristina Canuto. *See* Silva
Sauerland, Stefan. *See* Hulstaert
Schuller, Tara. *See* Henshall
Schumacher, Ines. *See* Zechmeister
Schwartz, J. Sanford. *See* Drummond
Sharp, Linda. *See* Hanly
Shepherd, Jonathan. *See* Hartwell
Shojania, Kaveh. *See* Chan
Siebert, Uwe. *See* Drummond
Sigal, Ronald J. *See* Coyle
Silva, Everton N. *See* Galvao
Silva, Marcus T. *See* Galvao
Silva, Marcus Tolentino, Rosimery Terezinha de Almeida, Cintia Maria Gava, Taís Freire Galvão, Edina Mariko Koga da Silva, Vania Cristina Canuto Santos, Misani Akiko Kanamota Ronchini, Aline Monte de Mesquita, Flávia Tavares Silva Elias, Alexandre Lemgruber Portugal d'Oliveira, and Álvaro Nagib Atallah. Brazilian health technology assessment bulletin: Editorial process, dissemination strategies, critical appraisal, and initial impact, 65
Simes, R. John. *See* Staub
Simpson, Sue. *See* Gutierrez-Ibarluzea
Simpson, Sue. *See* Packer
Sintonen, Harri. *See* Mäklin
Skally, Mairead. *See* Hanly
Smith, Susan M. *See* Gillespie
Sorensen, Sonja V., Jo Wern Goh, Feng Pan, Connie Chen, Denise Yardley, Miguel Martín, Kevin Knopf, Ágnes Benedict, Carla Giorgetti, and Shrividya Iyer. Incidence-based cost-of-illness model for metastatic breast cancer in the United States, 12
Soto-Pedre, Enrique. *See* Varela-Lema
Staub, Lukas P., Suzanne Dyer, Sarah J. Lord, and R. John Simes. Linking the evidence: Intermediate outcomes in medical test assessments, 52
Stegenga, Heather. *See* Lyratzopoulos
Stein, Ken. *See* Lu
Stevens, Andrew. *See* Packer
Stordeur, Sabine. *See* Hulstaert
Sullivan, Sean D. *See* Drummond
Sullivan, Sean D. *See* Pichon-Riviere
Sutherland, Lloyd R. *See* Leggett
- Tal, Orna, and Nina Hakak. Early awareness and alert systems for medical technologies in Israel, 333
Tan, Siok Swan, Clazien A. M. Bouwmans, Frans F. H. Rutten, and Leona Hakkaart-van Roijen. Update of the Dutch Manual for costing in economic evaluations, 152
Tant, Elizabeth. *See* Gartlehner
Tarride, Jean-Eric. *See* Lim
Thanh, Nguyen Xuan, Andy Chuck, Arto Ohinmaa, and Philip Jacobs. Benefits of pharmaceutical innovation: The case of simvastatin in Canada, 390
Tordoff, June. *See* Ragupathy
Tripp, Tim. *See* Chan
Turunen, Juha. *See* Asseburg
- Vaca, Claudia P. *See* Pichon-Riviere
van Brabant, Hans. *See* Hulstaert
van der Wilt, Gert Jan. *See* Hofmann
Vardeva, Kawitha. *See* Cooper
Varela-Lema, Leonor, Alberto Ruano-Ravina, Teresa Cerdá Mota, Nora Ibargoyen-Roteta, Inaki Imaz, Inaki Gutiérrez-Ibarluzea, Juan Antonio Blasco-Amaro, Enrique Soto-Pedre, and Laura Sampietro-Colom. Post-introduction observation of healthcare technologies after coverage: The Spanish proposal, 285
Varela-Lema, Leonora, Jeanette Punal-Riobóo, Beatriz Casal Acción, Alberto Ruano-Ravina, and Marisa López García. Making processes reliable: A validated PubMed search strategy for identifying new or emerging technologies, 452

- Vinck, Imgard. *See* Hulstaert
Vondeling, Hindrik. *See* Hulstaert
- Wasiak, Radek. *See* Kolasa
Watt, Amber M., Cameron D. Willis, Katherine Hodgetts, Adam G. Elshaug, and Janet E. Hiller, for the ASTUTE health study group. Engaging clinicians in evidence-based disinvestment: Role and perceptions of evidence, 211
Wells, George A. *See* Coyle
West, Suzanne L. *See* Gartlehner
Wild, Claudia. *See* Mad
Willis, Cameron D. *See* Watt
- Yardley, Denise. *See* Sorensen
Youn, Ji-Hee, Joanne Lord, Karla Hemming, Alan Girling, and Martin Buxton. Bayesian meta-analysis on medical devices: Application to implantable cardioverter defibrillators, 115
- Zaniolo, Orietta. *See* Pradelli
Zarrabi, Mahmood. *See* Leggett
Zechmeister, Ingrid, and Ines Schumacher. The impact of health technology assessment reports on decision making in Austria, 77
Zhao, Fei-Li. *See* Gao

THE 3RD CAMBRIDGE CONSORTIUM FOR BIOETHICS EDUCATION

Working Together to Shape the Future


June 19-21, 2013

Columbia Global Centers / Europe at Reid Hall / Paris, France

Bringing together international leaders in bioethics education to share experiences, program models, and innovative approaches to bioethics training.

For further information and to register, email Joon Moon at
jmoon@cambridge.org

cambridgebioethics.com



CAMBRIDGE
UNIVERSITY PRESS



International Journal of Technology Assessment in Health Care

Instructions for Contributors

The editors welcome submissions of articles that deal with the wide range of topics related to assessment for health care policy and practice, including issues of technology diffusion, economics, ethics, law, and social and cultural perspectives. All manuscripts are screened by the Editors and members of the Editorial Board. Those that pass proceed to an international review process, which usually is completed within 4 to 10 weeks. Accepted manuscripts will be published within 4 to 6 months. Articles must be in English. Spelling, capitalization, and punctuation should conform to the 15th Edition of *The Chicago Manual of Style* (University of Chicago Press).

MANUSCRIPT SUBMISSION AND REVIEW. All manuscript submissions to the *International Journal of Technology Assessment in Health Care* must be made electronically via ScholarOne Manuscripts, at the following website address:

<http://mc.manuscriptcentral.com/thc>

Complete instructions are provided on this website. Please follow the instructions on the website to avoid delays. The instructions will prompt the author to provide all necessary information, including the corresponding author's contact information, which includes complete mailing address, phone and fax numbers, and an e-mail address. The website also requests suggested reviewers. The website will automatically acknowledge receipt of the manuscript and provide a manuscript reference number. Every effort will be made to provide the author with a rapid review. Correspondence should be sent *by email only* to Marjukka Mäkelä at: IJTAHC@thl.fi.

PREPARATION OF MANUSCRIPT. The entire manuscript (in Word, RTF or PDF format), including all notes and references, must be typed, *double-spaced* on 8½ × 11 inch or A4 page sizes, with at least 1-inch (2.54 cm) margins. Manuscript pages should be numbered consecutively. Manuscripts should be arranged as follows: 1) cover sheet with title and short title; 2) abstract and key words; 3) acknowledgments, including source of funding; 4) text; 5) references; 6) tables with titles; and 7) figures, with captions on a separate page. Manuscripts should typically have *no more than 4,000 words*—including the abstract, which should not exceed 250 words. There should be no more than a total of four tables and illustrations together and no more than 25 references. Tables and illustrations exceeding these limits may be posted on the Journal's web site (www.journals.cambridge.org/thc) as supplementary materials. Supplementary figures and tables should be numbered separately from the figures and tables in the printed issue, beginning with Supplementary Figure 1 and Supplementary Table 1. Where relevant, all manuscripts should include one paragraph on the policy implications of the findings of the study. Acronyms should be clearly spelled out on first use. The use of product trade names should be avoided; generic names should be used except where discussion of proprietary brands is essential to the manuscript.

COVER SHEET AND COVER LETTER. A cover letter, signed by all authors, must attest that 1) each named author contributed to both the conception/design and/or analysis/interpretation of the project and the writing of the paper; 2) each has approved the version being submitted; and 3) the content has not been published nor is being considered for publication elsewhere.

As relevant to the content of the paper, the letter should also attest to the fact that any research with human or animal subjects conforms to the legal and standards of the country in which it was performed. *All authors must disclose any financial arrangements with companies whose products are discussed in the paper or their competitors*; such information will not be revealed to reviewers but may be included in a suitable format in the final publication if the manuscript is accepted. The cover letter should also provide all authors' full names, professional degrees, and institutional mailing addresses.

The cover sheet should list the article's title, the name, complete mailing address, telephone and fax numbers, and e-mail address of the corresponding author, and a short title (50 characters or less) for the running head.

ABSTRACT AND KEYWORDS. A 100- to 250-word abstract, submitted on a separate page, should *summarize* the objectives of the study or analysis, the article's major arguments and/or results, and its conclusions/recommendations. *Abstracts must be submitted in four sections:* Objectives; Methods; Results; and Conclusions, except where the subject and/or format of the article do not permit. Three to five key words, using terms from the Medical Subject Headings from *Index Medicus*, should follow the abstract.

REFERENCES AND NOTES. Bibliographic citations in the text should be indicated by numbers in parentheses usually at the end of the sentence after the period. When authors are mentioned in the text, the citation number should immediately follow the name(s) as follows:

In-text citations: "Jones and Smith (7) maintained that. . ."

The reference list must be in alphabetical order If a work has more than five authors, the first three authors should be listed, followed by et al. Abbreviate journal titles according to the listing in the current *Index Medicus*.

Book: 1. Jones AB, Smith JK. *Computer diagnosis and results*. New York: Penta Publishers; 1998.

Journal: 1. Jones AB, Smith JK. The relationship between health needs, the hospital, and the patient. *J Chron Dis*. 1995;32:310-312.

Article in edited work: 1. Jones AB, Smith JK. The diagnostic process. In: Brown R, Wilson T, eds. *New technology and its medical consequences*, vol. 1. New York: Apple Publishers; 1992:101-134.

In the reference list, do not include material that has been submitted for publication but has not yet been accepted. This material, with its date, should be noted in the text as "unpublished data" as follows: **Unpublished data:** "Similar findings have been noted by L. W. Smith (unpublished data, 1998)."

The Journal does not accept footnotes or appendices.

TABLES AND FIGURES. Tables and figures should be numbered consecutively. All tables and figures must have a caption and must be cited in the text. Abbreviations in tables and figures should be avoided, except in the case of acronyms already used in the text. Table footnotes appear directly after the table; table references follow the footnotes. Figures must be submitted in Excel, PageMaker, or equivalent.

PERMISSIONS. Authors are responsible for obtaining written permission to publish material for which they do not own the copyright. Contributors will be asked to assign their copyrights to Cambridge University Press.

OPEN ACCESS. Our standard copyright forms allow Open Access Archiving (for instance posting the Accepted Manuscript in an Institutional Repository or on a personal webpage). Authors can also choose to publish Open Access (making articles freely available for non-commercial use) in a large number of our Journals by using Cambridge Open Option. For complete information on all the options available please visit

<http://journals.cambridge.org/OpenAccess>

COPYEDITING AND PROOFREADING. The publishers reserve the right to copyedit and proofread all accepted articles. Page proofs will be sent to the lead author for final review.

REPRINTS. Reprints may be purchased if ordered at proof stage.



International Journal of
**Technology Assessment
in Health Care**

Official Journal of Health Technology Assessment International

Featured in this issue

EDITORIAL

Martikainen J.: Process of reimbursing medicines

POLICIES

Franken M et al.: Comparison of European drug reimbursement systems

Cleemput I et al.: Legitimacy of European drug reimbursement systems

Ragupathy R et al.: How PHARMAC operates in NZ

Frønsdal K et al.: HTA – regulatory interaction initiatives

ASSESSMENTS

Asseburg C et al.: Cost-effectiveness of triptans in migraine

Thanh N et al.: Monetary benefits of pharmaceutical innovation

Hartwell D et al.: Shortened treatment for chronic hepatitis C

Cooper K et al.: Evaluation of prevention intervention for STIs

Hanly P et al.: Review of cost-effectiveness of CT-colonography

Berti E et al.: Impact of computed tomography coronary angiography

Poggio R et al.: Cost effectiveness of resynchronization therapy

Gao L et al.: CUA of Liraglutide in T2DM patients in China

Attieh R.: HTA in low- and middle-income countries

METHODS

Varela-Lema L et al.: Search strategy for early warning systems

Sampietro-Colom L et al.: Decision support tool for hospital HTA